Hajijama Sameera, Marashi Mahmoud, Ho Samuel B
Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai Healthcare City, Dubai, United Arab Emirates.
Department of Medicine, Mediclinic City Hospital, Dubai Healthcare City, Dubai, United Arab Emirates.
Case Rep Gastroenterol. 2025 May 13;19(1):340-351. doi: 10.1159/000544927. eCollection 2025 Jan-Dec.
Wilson's disease (WD) is a rare genetic condition characterized by impaired copper metabolism and can rarely present as acute liver failure with an associated high mortality rate. Treatment often requires liver transplantation, and few rescue treatments have been shown to be effective by randomized trials. This is a case report and scoping literature review on plasmapheresis in acute liver failure due to WD.
We report a case of a previously undiagnosed 32-year-old female who presented with acute liver failure due to WD. Initial severity indices (MELD = 31 and RWPI - Revised Wilson Prognostic Index = 14) warranted liver transplant referral; however, no facilities were available. The patient was managed by two sessions of plasmapheresis with plasma exchange with persistent improvement in MELD score over 1 week. Subsequent ongoing chelation therapy resulted in a total reversal of clinical liver disease over 2 years. Literature review resulted in 74 patients reported to have been treated with plasmapheresis for WD and acute liver failure. Of these, 40% survived without transplant. Out of the total patients reported, 54 patients had an available NWI score, with 46 patients having a high-risk score of ≥11 (85%) and 8 patients had a score <11 (15%). Of the 46 patients with a score ≥11, 21 (46%) recovered without liver transplantation, 16 (35%) underwent liver transplantation, 8 (17%) died of liver failure, and 1 (∼2%) died of sepsis. Of the 8 patients with a score of <11, 4 (50%) recovered without a liver transplantation, and 4 (50%) underwent transplantation.
The outcomes observed in the literature and the favorable outcome of our patient suggest an emphasis on the use of urgent plasmapheresis with plasma exchange as an initial intervention for acute liver failure in WD, although further randomized controlled trials are needed for determining the optimal dose and duration of treatment.
威尔逊病(WD)是一种罕见的遗传性疾病,其特征为铜代谢受损,极少情况下可表现为急性肝衰竭,死亡率较高。治疗通常需要肝移植,且很少有挽救治疗方法经随机试验证明有效。本文是一篇关于WD所致急性肝衰竭行血浆置换的病例报告及范围界定文献综述。
我们报告一例32岁此前未确诊的女性患者,因WD出现急性肝衰竭。初始严重程度指标(终末期肝病模型评分[MELD]=31,修订的威尔逊预后指数[RWPI]=14)表明有必要转诊进行肝移植;然而,当时没有可用的医疗设施。该患者接受了两次血浆置换治疗,血浆置换后MELD评分在1周内持续改善。随后持续进行螯合治疗,2年内临床肝病完全逆转。文献综述发现,有74例患者报告接受了血浆置换治疗WD及急性肝衰竭。其中,40%未经移植存活。在报告的所有患者中,54例有可用的NWI评分,46例(85%)为高危评分≥11,8例(15%)评分<11。在46例评分≥11的患者中,21例(46%)未进行肝移植而康复,16例(35%)接受了肝移植,8例(17%)死于肝衰竭,1例(约2%)死于败血症。在8例评分<11的患者中,4例(50%)未进行肝移植而康复,4例(50%)接受了移植。
文献中观察到的结果以及我们患者的良好结局表明,应强调紧急进行血浆置换作为WD所致急性肝衰竭的初始干预措施,不过仍需要进一步的随机对照试验来确定最佳治疗剂量和疗程。